Moderna, a biotechnology company that is currently advancing a leading COVID-19 vaccine candidate, recently stated that it would not enforce its vaccine patents during the current health crisis. In light of this announcement, Troutman Pepper Intellectual Property Partners Maia Harris, Andrew Zappia and Louis DelJuidice discuss enforcing IP during the pandemic. Their discussion analyzes patent enforcement in the context of litigation, prosecution, USPTO proceedings, and licensing.
